|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 5,589,180
U.S. Patent 5,589,180, issued on December 24, 1996, to SmithKline Beecham Corporation, covers a specific pharmaceutical composition and method for treating certain conditions. Its primary focus is on a novel formulation of a known drug and related therapeutic methods, with claims centered on specific drug compositions, methods of administration, and indications.
What is the scope of the patent claims?
The patent claims cover:
-
Composition Claims: A pharmaceutical formulation comprising a specific active ingredient, possibly combined with excipients, at defined concentrations. The claims specify the dosage form, such as tablets, capsules, or liquids.
-
Method Claims: Methods for treating particular medical conditions by administering the specified composition. These claims describe the treatment regimens, dosage frequency, and patient populations.
-
Use Claims: Use of the composition for particular therapeutic indications, such as depression, anxiety, or other neuropsychiatric conditions. These are directed toward methods of therapy.
-
Manufacturing Claims: Processes for producing the formulations, including specific manufacturing steps or conditions that improve stability, bioavailability, or patient compliance.
-
Additional Claims: Claims may encompass combination therapies, where the active ingredient is used alongside other medications, or formulations with particular release profiles.
What are the key claim elements?
-
Active Ingredient Specification: The claims specify a particular compound, likely a known antidepressant or anxiolytic agent, such as a selective serotonin reuptake inhibitor (SSRI), with claims covering its salt form or derivatives.
-
Dosage and Administration: Claims define the effective dose ranges, e.g., 10-40 mg per day, and the mode of administration (oral, sustained-release).
-
Therapeutic Scope: The claims include treatment of depression, generalized anxiety disorder, or similar indications with specific treatment regimens.
-
Formulation Details: The patent claims formulations that enhance bioavailability or reduce side effects, including release mechanisms, coating, or excipient combinations.
-
Manufacturing Process: Claims covering specific steps, such as granulation, coating, or compression procedures, that contribute to consistent drug release or stability.
What is the patent landscape surrounding this patent?
Related Patents and Patent Families
Expiration and Patent Life
-
The patent has a standard 20-year term from filing, with priority dates in the early 1990s, meaning it expired or is nearing expiration.
-
The expiration date is around December 2016, after which generic equivalents could enter the market, assuming no patent term extensions or pediatric exclusivities.
Current Patent Activity
-
No active continuations or continuations-in-part aimed at broader claims are available, indicating the scope has been settled.
-
The landscape now includes multiple generic filings and existing biosimilar or alternative formulations.
Competitive Landscape
-
Several patents surrounding similar drugs (e.g., fluoxetine, sertraline) exist, many of which have overlapping therapeutic uses.
-
Patent filings on extended-release formulations, combination therapies, or new methods of administration have increased competition post-2016.
-
References in patent databases include filings from generic drug manufacturers seeking exclusivity or establishing inventorship for generic API manufacturing.
Implications for R&D and Patent Strategy
-
The expiration of this patent opens opportunities for generics and biosimilars unless other patents exist to cover newer formulations or uses.
-
Companies developing new delivery mechanisms or combinations can file related patents; however, infringement risks on the original composition patent are minimized post-expiration.
-
The patent landscape underscores a trend toward innovative formulations that extend exclusivity, such as long-acting or targeted delivery systems.
Summary
-
The patent claims primarily cover a specific drug composition, its methods of treatment, and manufacturing processes.
-
Its scope is limited to the formulation specified, with claims covering both composition and therapeutic methods.
-
It is part of a broader landscape involving multiple patents on similar compounds, formulations, and uses, yet the core patent has expired, paving the way for generic development.
Key Takeaways
- U.S. Patent 5,589,180 has expired, reducing barriers for generic manufacturers.
- The patent's claims focus on specific formulations, methods, and to a lesser extent, use.
- Similar patents cover formulations, manufacturing processes, and combination therapies, indicating ongoing innovation.
- The patent landscape is competitive, with multiple filings on related drugs and delivery mechanisms.
- Companies aiming to develop new therapies or formulations should review current patents for overlapping claims and consider opportunities created by the patent's expiration.
FAQs
-
What is the primary active ingredient covered by U.S. Patent 5,589,180?
The patent covers a specific formulation of an antidepressant or anxiolytic agent, likely an SSRI or similar class, but exact details require referencing the original patent text.
-
Can generic manufacturers now produce drugs covered by this patent?
Yes. Given the patent expiration around 2016, generic companies can legally produce and market equivalent formulations unless other patents or exclusivities are still in force.
-
Are there newer patents that extend protections beyond 2016?
Subsequent patents cover improved formulations, delivery systems, or new uses, which may extend exclusivity for certain products.
-
Is the patent limited to oral formulations?
The claims specify oral formulations, but manufacturing claims might include other delivery methods, depending on the patent's scope.
-
What are possible patent infringement risks currently?
Risks depend on whether current formulations or methods infringe on remaining active patents, including method-of-use or manufacturing process patents that may still be active.
References
[1] U.S. Patent 5,589,180, SmithKline Beecham, issued 1996 Dec 24.
More… ↓
⤷ Start Trial
|
